Scholarlink

<p>Owing to their natural origin and biocompatibility, extracellular vesicles (EVs) are being recognized as next-generation vehicles for targeted drug delivery. Despite their potential as therapeutic carriers, EVs suffer from heterogeneity, low yields, limited cargo loading efficiency and rapid clearance by the mononuclear phagocyte system. Since the first EV-based clinical trial in 2005, more than 100 clinical trials have investigated the use of EVs as therapeutics and drug carriers. Despite this, no EV-based therapies have received regulatory approval to date. This gap between preclinical research activity and clinical translation underscores persistent scientific challenges and regulatory hurdles that continue to impede the advancement of EV-based therapeutics. In this Review, we examine the research articles published in the field between 2012 and 2024 (38,177 articles), highlighting key developments, persistent challenges and evolving assumptions. We review the current EV landscape and clinical trials, focusing on their organotropism and use as carriers for therapeutics. We compare their advantages and limitations in relation to other nanoparticles, such as lipid nanoparticles and liposomes, and examine how labelling strategies and cell sources influence EV biodistribution. Finally, we outline translational considerations for EV-based therapeutics and propose additional reporting standards, complementing the MISEV 2023 guidelines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The status of extracellular vesicles as drug carriers and therapeutics

  • 期刊论文

  • 发表日期：

    2026年2月5日

查看全文
  • Ameya P. Chaudhari,
  • Omar M. Budayr,
  • Emily E. Bonacquisti,
  • Caden C. Kussatz,
  • Mark S. Bannon,
  • Karissa J. Law,
  • Yusha Liu,
  • Matthew L. Bolton,
  • Patrick M. Glassman,
  • Leaf Huang,
  • Juliane Nguyen

摘要

Owing to their natural origin and biocompatibility, extracellular vesicles (EVs) are being recognized as next-generation vehicles for targeted drug delivery. Despite their potential as therapeutic carriers, EVs suffer from heterogeneity, low yields, limited cargo loading efficiency and rapid clearance by the mononuclear phagocyte system. Since the first EV-based clinical trial in 2005, more than 100 clinical trials have investigated the use of EVs as therapeutics and drug carriers. Despite this, no EV-based therapies have received regulatory approval to date. This gap between preclinical research activity and clinical translation underscores persistent scientific challenges and regulatory hurdles that continue to impede the advancement of EV-based therapeutics. In this Review, we examine the research articles published in the field between 2012 and 2024 (38,177 articles), highlighting key developments, persistent challenges and evolving assumptions. We review the current EV landscape and clinical trials, focusing on their organotropism and use as carriers for therapeutics. We compare their advantages and limitations in relation to other nanoparticles, such as lipid nanoparticles and liposomes, and examine how labelling strategies and cell sources influence EV biodistribution. Finally, we outline translational considerations for EV-based therapeutics and propose additional reporting standards, complementing the MISEV 2023 guidelines.